CVC Fund VIII (CVC) is to invest in Spectrum Medical group at a £1 billion valuation.
Spectrum Medical has grown rapidly over the past few years by bringing new and pioneering technologies to the cardiac bypass and ICU space.
Today, Spectrum Medical is focused on the development of becoming a single “solutions provider” of a platform of high-performance technologies that include Quantum Perfusion Systems, Quantum Informatics and Quantum Sterile Technologies. The combination of these world leading technologies creates an ecosystem of products which lead to enhanced clinical monitoring, greater patient safety and improved health economics.
CVC was advised by PWC and Freshfields; Spectrum Medical were advised by PWC, BPE and Rothschild.
